RxDoctor Payments Data

Kent Berkey, MD

Neurology · Washington, PANPI 1396943742

Payments from drug & device makers

$11,107in general payments, 2019–2025

Across 634 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novartis$1K
  • EMD Serono, Inc.$508
  • SK Life Science, Inc.$443
  • Acorda Therapeutics, Inc$443
  • Teva Pharmaceuticals USA, Inc.$427
  • plus $5K from 48 others

What the payments were for

  • Speaking & faculty fees$3023%
  • Food & beverage$10,63196%
  • Education$1742%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,107 in reported general payments places this provider in the 70th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$30,300
Medicare patients
153
Services billed
305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4687$959,063
OctagamImmun Globg(Igg)/Malt/Iga Ov5014$425,533
Kesimpta PenOfatumumab21$179,955
Rufinamide12$57,359
Aimovig AutoinjectorErenumab-Aooe49$54,151
Nurtec OdtRimegepant Sulfate42$43,581
XcopriCenobamate38$40,186
BriviactBrivaracetam20$28,170
Trokendi XrTopiramate24$27,618
Dalfampridine ErDalfampridine44$19,377
Lacosamide27$19,245
Emgality PenGalcanezumab-Gnlm24$18,133
AptiomEslicarbazepine Acetate12$14,641
Topiramate ErTopiramate26$13,868
NeuproRotigotine12$11,466

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$16$959,06387 claims
PfizerOctagam, Nurtec Odt$323$469,11356 claims
SK Life Science, Inc.Xcopri$443$40,18638 claims
UCB, Inc.Briviact, Neupro$346$39,63632 claims
Supernus Pharmaceuticals, Inc.Trokendi Xr$173$27,61824 claims
Sunovion Pharmaceuticals Inc.Aptiom$128$14,64112 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$198$2,84028 claims
Upsher-smith Laboratories LLCTopiramate$60$70174 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Washington

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →